MRI Contrast Agent Dye Lawsuit

Every year, thousands of people undergo MRIs that involve the use of gadolinium-based MRI contrast agent dyes like Omniscan and Magnevist. Recently, however, U.S. health regulators issued a class warning for these products regarding the potential for gadolinium retention. A growing number of MRI contrast dye lawsuits have also been filed in U.S. courts on behalf of patients who allegedly suffered from gadolinium toxicity or “Gadolinium Deposition Disease” due to their exposure to these agents.

MRI Contrast Agent Dye Lawsuit

Contact an MRI Contrast Dye Lawyer Today

The nationwide law firm of Bernstein Liebhard LLP is investigating legal claims on behalf of patients who developed chronic symptoms that may be associated with gadolinium toxicity or Gadolinium Deposition Disease allegedly associated with certain MRI contrast agents. To learn if you might qualify to file an MRI contrast dye lawsuit, please call (888) 994-5118.

Studies Suggest Gadolinium Deposits from MRI Contrast Dyes May be Retained in Brain

Gadolinium is a rare earth metal that is commonly found in the environment. When injected into the body, gadolinium-based contrast agents make tissues and abnormalities more visible on MRI scans. Gadolinium-based dyes were first approved by the U.S. Food & Drug Administration (FDA) in 1988, and nine such agents are now available for use in this country:

  • Dotarem
  • Eovist
  • Gadavist
  • Magnevist
  • Multihance
  • Ominiscan
  • Optimark
  • Prohance

In 2015, two studies were published that suggested these agents could leave behind potentially-toxic gadolinium deposits in patients’ brains. In March 2015, the journal Radiology published research involving cadaver brains which found such deposits in the brains of those that had received gadolinium injections, while the deposits were absent in those who had not received injections. That June, European researchers writing in Investigative Radiology reported that they had found similar deposits in the brains of rats injected with Omniscan.

Why are Plaintiffs Filing MRI Contrast Dye Lawsuits?

A growing number of lawsuits have recently been filed in U.S. courts on behalf of individuals who purportedly developed gadolinium toxicity or Gadolinium Deposition Disease following an MRI with a gadolinium-based contrast dye.

These plaintiffs claim that gadolinium deposits can be retained in the body, including the brain, following an MRI, leading to serious adverse events.

While Gadolinium Deposition Disease is not yet recognized by the medical community, plaintiffs contend that that gadolinium retention is causing a wide range of symptoms in patients with normal kidney function, including:

  • Persistent headaches
  • “Brain fog” and memory problems
  • Severe bone and joint pain
  • Skin thickening or discoloration
  • Burning pain (pins and needles) in arms, legs and/or torso

Their gadolinium lawsuits further charge that plaintiffs could have avoided their injuries and complications had the drugs’ makers provided doctors and patients with adequate warnings regarding the potential for gadolinium retention.

FDA Issues Class Warning for Gadolinium Retention from MRI Contrast Dyes

The FDA began reviewing the safety of gadolinium MRI contrast agents in July 2015. At that time, the agency asked doctors to limit the use of gadolinium-based agents to clinical circumstances in which the additional information provided by the contrast is necessary, and to reassess the necessity of repetitive gadolinium MRIs in established treatment protocols.

In December 2017, the FDA issued a class warning for gadolinium contrast dyes because of the risk that gadolinium could be retained in the brain or other parts of the body weeks, or even months, after a patient has undergone an MRI.

“To date, the only known adverse health effect related to gadolinium retention is a rare condition called nephrogenic systemic fibrosis (NSF) that occurs in a small subgroup of patients with pre-existing kidney failure,” the FDA said. “We have also received reports of adverse events involving multiple organ systems in patients with normal kidney function. A causal association between these adverse events and gadolinium retention could not be established.”

While the FDA had not yet linked gadolinium retention to any adverse events, it was requiring that the labels for all gadolinium-based MRI contrast dies be updated with a new Warning and Precaution regarding this risk. The agency also ordered the drugs’ manufacturers to include information about gadolinium retention in the Reactions, Pregnancy, Clinical Pharmacology, and Patient Instructions.

Among other things, the agency advised health care providers to consider the retention characteristics of each agent when choosing a gadolinium product for patients who may be at higher risk for retention, including:

  • Patients requiring multiple lifetime doses
  • Pregnant women
  • Children
  • Patients with inflammatory conditions

Finally, the FDA directed the drugs’ makers to create new Medication Guides for patients undergoing MRIs with gadolinium-based agents and to conduct human and animal studies to further assess the safety of these drugs.

Free Legal Reviews for Alleged Victims of Gadolinium Toxicity and Gadolinium Deposition Disease

Patients who suffered symptoms of gadolinium toxicity or Gadolinium Deposition Disease following an MRI may be entitled to compensation for:

  • Medical bills
  • Lost wages
  • Disability
  • Emotional distress
  • Pain and suffering
  • More

To learn more about filing an MRI contrast dye lawsuit, please contact our office today at (888) 994-5118.

  1. Inside Radiology (2013) “Gadolinium Contrast Medium (MRI Contrast agents)”
  2. Radiology Info (2013) “Contrast Materials”
  3. FDA (2010) “FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction”
  4. FDA (July 2015) “FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI)”
  5. FDA (December 2018) “FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings”
Last Modified: May 23, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content